Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

Madrid, Manuelito; Lo, Raymundo

doi:10.1186/bcr915

Cited by 37 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16] Studies on its use in archival breast cancer specimens have shown it to be a practical, cost-effective and valid alternative to fluorescent in situ hybridization in detecting gene amplification. 14,17 Instead of using a fluorescent dye, chromogenic in situ hybridization uses a peroxidase reaction to detect the gene probe. The hybridization result can be visualized under a routine light microscope.…”

mentioning

confidence: 99%

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

et al. 2005

View full text Add to dashboard Cite

Recent data suggest that detection of epidermal growth factor receptor protein by immunohistochemistry (IHC) does not predict response to the antiepidermal growth factor receptor drug, cetuximab, in patients with colorectal carcinoma. In searching for foundation for further investigation to optimize patient selection for cetuximab therapy, this study sought to exploit the tissue microarray and chromogenic in situ hybridization techniques to evaluate the status of epidermal growth factor receptor gene amplification in colorectal cancer and its relationship with protein expression by IHC. The study included 158 primary or metastatic colorectal adenocarcinomas. Immunohistochemical results were scored as 0-3 þ based on the intensity of membrane staining. The in situ hybridization signals were counted in 30 nuclei per tissue core. Overall, the rate of tissue loss was 7%, yielding 147 analyzable cases: 123 primary, 24 metastatic. Positive immunohistochemical staining of any intensity was detected in 85% (105/123) of primary and 79% (19/24) of metastatic tumors, whereas gene amplification (45 gene copies/nucleus) was only seen in 12% (15/123) of primary and 8% (2/24) of metastatic tumors. Only 2/15 primary and 1/2 metastatic tumors that showed gene amplification were amplified at a high level (410 gene copies/nucleus). Although a positive correlation was detected between the intensity of protein expression and the likelihood of gene amplification in both the primary (P ¼ 0.01) and the metastatic (P ¼ 0.05) tumors, IHC had a low specificity (17% in primary, 23% in metastatic) in predicting gene amplification. Conversely, all tumors that did not express the protein by IHC lacked gene amplification. Thus, this study shows that only a small fraction of epidermal growth factor receptor-positive colorectal carcinomas detected by IHC are associated with gene amplification. Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximabbased therapy. The epidermal growth factor receptor (EGFR) is a member of the HER tyrosine kinase growth factor receptor family, and is involved in signaling pathways affecting cell growth. [1][2][3][4] Recent studies have shown that EGFR expression is present in approximately 60-80% of colorectal carcinomas 5,6 and the receptor has emerged as a rational target for anticancer therapy in these tumors. 2,7 Cetuximab is a human-murine chimeric monoclonal antibody that specifically blocks the EGFR. Several clinical trials have demonstrated activity of cetuximab in patients with advanced colorectal carcinoma 3,4 and the drug is currently licensed in the US and Switzerland for use in such patients.

show abstract

mentioning

confidence: 99%

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…This new assay based on the hybridization of a specific DNA probe and a peroxidase reaction allows the assessment of the gene copy number in neoplastic cells using as internal hybridization control normal cells [13]. We found amplification by this procedure in 17.6% of the cases, which correlated in 92.5% with the IHC results, with the highest levels of concordance among cases that were either completely negative (0) or strongly positive by IHC analysis [2,4,6,10,11,13,14,[16][17][18]24,25]. The negative predictive rate was 100% for cases with score (0) and 97.8% for cases with score (1+), indicating that IHC is specific in this group of results.…”

Section: Discussionmentioning

confidence: 84%

“…It appears to be an attractive method for clinical HER2 analysis owing to its specific targeting of neoplastic cells and retrospective potential. Comparison of chromogenic in situ hybridization (CISH) results with IHC or FISH has shown good correlation in recent studies [13][14][15][16][17][18][19][20][21][22][23]. Nevertheless, little data are available regarding the clinical value of CISH [2,18,[24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node–negative breast carcinoma: prognostic relevance

et al. 2007

View full text Add to dashboard Cite

“…HER-2 status is an important prognostic factor for cancer that plays a key function in initiation, development, and spreading of some cancers (breast and gastric cancer). Patients with positive HER-2 breast cancer have lesser survey than those with HER-2 negative tumors (10)(11)(12). Due to high HER-2 over-expression rate in gastric canRazavi Int J Med.…”

Section: Discussionmentioning

confidence: 99%

Assessment the of Amplification HER-2/neu Gene by Chromogenic In Situ Hybridization (CISH) Compared to Immunohistochemistry (IHC) Method in Gastric Cancer

et al. 2018

View full text Add to dashboard Cite

Background: Gastric cancer has a high mortality rate and often has a poor treatment outcome. The HER2/neu gene target therapy has been known as a potential way for treatment. Objectives: The goal of our study was assessment the relation between chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) methods in determining the best diagnostic method for gastric cancer. Methods: In this historical cohort study, 50 gastric cancer samples were analyzed by CISH and IHC. The relation between clinicalpathological parameters of HER2/neu was also analyzed. Alive patients were followed from 2009 through 2012 for the main outcomes (mortality). The results of these two methods, in terms of sex, age, tumor size, grading, staging, tumor location, metaplasia, presence of necrosis and ulceration, vascular invasion, the TNM system, mucin or signet producing adenocarcinoma cells and patient survival rates were compared. Results: There was no significant difference between IHC and CISH regarding the sex, age, tumor size, grading, staging, tumor location, metaplasia, presence of necrosis and ulceration, vascular invasion, the TNM system, mucin or signet producing adenocarcinoma cells and patient survival rates. Comparison of TNM scores by these two methods showed no significant relationship between IHC and staging, but a statistically significant difference between CISH and different N staging, (P < 0.05) was assessed. Conclusions:Comparison between IHC and CISH showed the only significant relationship between CISH and different N staging. Therefore, low amplified CISH was a better diagnostic method for gastric cancer, compared to low expression in IHC.

show abstract

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

Abstract: Background Chromogenic in situ hybridization (CISH) is emerging as a practical, cost-effective, and valid alternative to fluorescent in situ hybridization in testing for gene alteration, especially in centers primarily working with immunohistochemistry (IHC).

Cited by 37 publications

References 31 publications

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node–negative breast carcinoma: prognostic relevance

Assessment the of Amplification HER-2/neu Gene by Chromogenic In Situ Hybridization (CISH) Compared to Immunohistochemistry (IHC) Method in Gastric Cancer

Contact Info

Product

Resources

About